Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2025-01-21 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2024年年度业绩预告' which translates to '2024 Annual Performance Forecast'. It provides estimated financial results for the full year 2024, including expected net profit loss ranges and explanations for performance changes. It explicitly states that the data is preliminary, unaudited, and that detailed audited financial data will be disclosed in the 2024 Annual Report. The document is short (846 characters) and serves as a forecast or earnings guidance rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results or forecasts. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and is a forecast rather than actual results. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-01-21 Chinese
关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (515 characters) regarding a subsidiary company receiving a High-Tech Enterprise Certificate and the associated tax benefits. It is an official disclosure by the board but does not contain financial statements, management discussion, or detailed report data. It is not a full report but an announcement of a corporate event related to tax status and recognition. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-01-21 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司2024年度现场培训情况报告
Regulatory Filings Classification · 90% confidence The document is a report from a securities company about a training session conducted for the controlling shareholders, directors, supervisors, and senior management of a listed company. It details the date, location, participants, and content of the training, as well as the conclusion that the training was effective. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no regulatory certifications. The document is a report on a compliance-related training session, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not an announcement but a report on the training event itself. Given the nature of the content, it best fits under Regulatory Filings (RNS) as a general compliance-related report that does not fit other specific categories.
2025-01-17 Chinese
关于公司及子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' application for a comprehensive credit line from banks. It includes details about the board meeting approving this financing action and the intended use and impact of the credit line. There are no financial statements, earnings data, or detailed financial analysis present. The document is focused on capital/financing activities, specifically bank credit facilities. It is not a full financial report, earnings release, or regulatory certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not merely an announcement of a report but a substantive update on financing activities.
2025-01-15 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the decision to use idle funds for cash management, including details about the amount, purpose, risk control, and approvals from the board and supervisory committee. It is a formal disclosure of a corporate decision related to capital management but does not contain financial statements or detailed financial results. The document length is short (1975 characters) and it is an announcement of a corporate action rather than a financial report or earnings release. This fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital usage.
2025-01-15 Chinese
关于公司为子公司提供担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the provision of guarantee limits for its subsidiaries' financing activities. It includes detailed information about the guarantee amounts, the subsidiaries involved, their financial status, and the board and supervisory committee's opinions on the matter. The document does not contain a full financial report or earnings data but rather focuses on a specific corporate action related to financing guarantees. It is not a full annual or interim report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and guarantees provided to subsidiaries.
2025-01-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.